Skip to main content

Day: March 5, 2020

Kelly Services® Adds D. Hugo Malan to Senior Leadership Team; Named President of New STEM Business Unit

TROY, Mich., March 05, 2020 (GLOBE NEWSWIRE) — Kelly Services Inc. (Nasdaq: KELYA, KELYB), a global leader in providing workforce solutions, today announced the hiring of D. Hugo Malan as Senior Vice President and President of the STEM specialty business being formed as part of Kelly’s new structure announced in February by President and Chief Executive Officer Peter Quigley.With approximately 20 years of wide-ranging business leadership experience, Malan brings a fresh perspective to Kelly as the company accelerates its transformation into a leading specialty talent solutions provider. Malan will have overall responsibility for Kelly’s Science, Engineering and IT business portfolios and related product offerings while driving strategy and seamless execution of all aspects of the STEM business.“We are thrilled to welcome to our...

Continue reading

Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update

Conference Call and Webcast Scheduled Today at 8:45 AM ETWARMINSTER, Pa., March 05, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its fourth quarter and year end 2019 financial results, confirms 2020 corporate objectives and provides pipeline update.“Arbutus is focused on developing a portfolio of medicines with different mechanisms of action that we believe could provide a functional cure for people with chronic hepatitis B,” said William Collier, Arbutus’ President and Chief Executive Officer. “Our key objectives for 2020 are to complete and report results from the Phase 1a/b clinical trial of AB-729, our proprietary subcutaneous RNAi agent, and rapidly advance our next-generation oral capsid inhibitor, AB-836, through IND-enabling studies...

Continue reading

Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update

SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it will report fourth quarter and full year 2019 financial results and provide a corporate update on Thursday, March 12, 2020. Harpoon’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT.The live call may be accessed by dialing 866-951-6894 for domestic callers and 409-216-0624 for international callers and entering the conference code: 5468929. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.harpoontx.com.About Harpoon TherapeuticsHarpoon Therapeutics is a clinical-stage immunotherapy company developing a novel...

Continue reading

Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update

HOUSTON, March 05, 2020 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the fourth quarter and full year 2019 after the close of U.S. markets on Thursday, March 12, 2020. Management will host a webcast and conference call at 5 p.m. ET / 2 p.m. PT that day to discuss the financial results and provide a corporate update.The live call may be accessed by dialing 877-407-3103 (U.S. domestic) and 201-493-6791 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investors & Media section...

Continue reading

CloudMD Software & Services Inc. Announces Symbol Change on OTCQB

VANCOUVER, British Columbia, March 05, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (CSE: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a Company focused on revolutionizing the delivery of healthcare, is pleased to announce  that, in connection with CloudMD’s recent name change, its ticker symbol on the OTCQB has changed from “PHGRF ” to “DOCRF” effective today.No action is needed from the Company’s current shareholders relative to the ticker symbol change.For more information on CloudMD visit www.cloudMD.ca.ON BEHALF OF THE BOARD OF DIRECTORS“Dr. Essam Hamza, MD”Chief Executive Officer                                                                                                             About CloudMD Software & ServicesCloudMD is digitizing the delivery...

Continue reading

NexTech’s Revolutionary 3D AR Capture App “ARitize 360” Now Available for Early Access Signup

NEW YORK and TORONTO, March 05, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (the “Company” or “NexTech”) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) NexTech, the industry leader in the rapidly growing augmented reality (AR) space, is excited to announce early access for one-hundred brands and businesses of its revolutionary 3D/AR capture app previously called CaptureAR, now rebranded as “ARitize360”.SEE VIDEO DEMO HEREEARLY ACCESS SIGNUP HEREThe company is offering free early access for one-hundred brands and businesses before launching a stand alone dual platform app called “ARitize360”.  The app will employ the freemium business model, whereby a user gets a free 3D scan. However, a user will be billed for additional scan “packs” as well as be charged a monthly subscription fee for hosting the 3D asset. Together the two could add substantial...

Continue reading

Zai Lab to Announce Financial Results for the Full Year Ended December 31, 2019 and Corporate Updates on March 19, 2020

— Company to host Conference Call and Webcast on March 19, 2020 at 8:30 a.m. ETSHANGHAI, China and SAN FRANCISCO, March 05, 2020 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced it will report financial results for the full year ended December 31, 2019 and corporate updates before the market opens on Thursday, March 19, 2020 and host a conference call at 8:30 a.m. ET. On the call, Zai Lab’s senior management team will also provide an update on the Company’s business and upcoming milestones.The live webcast and a replay may be accessed by visiting the Company’s website at http://ir.zailaboratory.com. Alternatively, please call (866) 5194004 (U.S.), +65 67135090 (International), 4006208038 (China), +852 30186771 (Hong Kong), or +44...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.